Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCigna Clobazam Coverage Update | OpenPayer
    Ask Trek AI about this page
    CurrentCignaPolicy IP0106

    Antiseizure Medications - Clobazam Products

    Customize your policy alerts

    Sign up for Cigna Policy IP0106 alerts

    Get alerted when Policy IP0106 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical-necessity coverage for clobazam products, including Onfi, generic clobazam, and Sympazan, for commercially insured members. It applies to initial and continuation therapy for Lennox-Gastaut syndrome, Dravet syndrome, and treatment-refractory seizures or epilepsy.

    Policy Summary
    PayerCigna
    PolicyAntiseizure Medications - Clobazam Products
    Policy CodePolicy IP0106
    Change TypeAdministrative updateno material clinical or coverage changes
    Effective DateNovember 15, 2026
    Last ReviewOct 29, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and have initial clobazam therapy prescribed by or provided in consultation with a physician who specializes in the condition being treated.
    SourceLink
    POLICY UPDATE CHANGES

    The policy title was updated from "Clobazam" to "Antiseizure Medications - Clobazam Products."

    A Preferred Product Table was added for employer plans.

    The October 29, 2026 review and November 15, 2026 effective-date update made no criteria changes.

    3covered clinical use categories
    ≥ 2 yearsminimum age for initial therapy
    1 yearapproval duration

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2named product lines covered
    Other usesnot medically necessary
    0criteria changes reported

    Covered and Noncovered Uses

    Lennox-Gastaut syndrome

    Covered when ONE of the following is met; approval is for 1 year.

    Lennox-Gastaut syndrome coverage pathways

    • Initial therapy

      • Initial-therapy requirements

        • Age requirement

          • The patient is at least 2 years of age.Age ≥ 2 years
        • Prior antiseizure therapy

          • The patient has tried and/or is concomitantly receiving at least two other antiseizure medications.
          • The patient has tried and/or is concomitantly receiving one of the following: lamotrigine, topiramate, rufinamide, felbamate, Fintepla (fenfluramine oral solution), or Epidiolex (cannabidiol oral solution).
        • The medication is prescribed by or in consultation with a neurologist.
        • Preferred product criteria are met for the requested product.
    • Continuation therapy

      • The patient is currently receiving clobazam and is responding to therapy as determined by the prescriber.

        Examples of response include reduced seizure severity, frequency, and/or duration from baseline before clobazam was initiated.

    Dravet syndrome

    Covered when ONE of the following is met; approval is for 1 year.

    Dravet syndrome coverage pathways

    • Initial therapy

      • Initial-therapy requirements

        • The patient is at least 2 years of age.Age ≥ 2 years
        • The medication is prescribed by or in consultation with a neurologist.
        • Preferred product criteria are met for the requested product.
    • Continuation therapy

    Treatment-refractory seizures or epilepsy

    Covered when ONE of the following is met; approval is for 1 year.

    Treatment-refractory seizures or epilepsy coverage pathways

    • Initial therapy

      • Initial-therapy requirements

        • The patient is at least 2 years of age.Age ≥ 2 years
        • The patient has tried and/or is concomitantly receiving at least two other antiseizure medications.At least two other antiseizure medications

          Examples include valproic acid, lamotrigine, topiramate, clonazepam, levetiracetam, zonisamide, rufinamide, and felbamate.

        • The medication is prescribed by or in consultation with a neurologist.

    Conditions Not Covered

    Not medically necessary when used for any other indication.

    Noncovered use

    • Clobazam is used for an indication other than Lennox-Gastaut syndrome, Dravet syndrome, or treatment-refractory seizures or epilepsy.

      Any other use is considered not medically necessary.

    Clobazam products are covered for Lennox-Gastaut syndrome, Dravet syndrome, or treatment-refractory seizures or epilepsy when the applicable initial-therapy or continuation-therapy requirements are met. Initial therapy generally requires the patient to be at least 2 years old, with neurologist involvement and applicable prior antiseizure therapy or preferred-product requirements. Continuation therapy requires current clobazam use with a prescriber-determined response. Approval is for 1 year.

    Clobazam use outside the covered indications—Lennox-Gastaut syndrome, Dravet syndrome, and treatment-refractory seizures or epilepsy—is not medically necessary.

    Clobazam for any other indication is considered not medically necessary.

    Clobazam for any use other than the policy’s covered indications is considered not medically necessary.

    Initial Therapy Requirements

    Lennox-Gastaut syndrome initial therapy

    Approve for 1 year when all initial-therapy requirements are met.

    • The patient is at least 2 years of age.Age ≥ 2 years
    • Prior antiseizure therapy

      • The patient has tried and/or is concomitantly receiving at least two other antiseizure medications.
      • The patient has tried and/or is concomitantly receiving one of the following: lamotrigine, topiramate, rufinamide, felbamate, Fintepla (fenfluramine oral solution), or Epidiolex (cannabidiol oral solution).
    • The medication is prescribed by or in consultation with a neurologist.

    Continuation of Therapy

    Continuation of clobazam

    Approve for 1 year when the patient is currently receiving clobazam and is responding to therapy as determined by the prescriber.

    Continuation therapy

    • The patient is currently receiving clobazam.
    • The patient is responding to therapy as determined by the prescriber.

      Examples of response include reduced seizure severity, frequency, and/or duration from baseline before initiation of clobazam.

    Brand Onfi Step Requirement

    StepProduct requestedRequirement
    1Brand Onfi tablets or oral suspensionThe patient must have tried the bioequivalent generic clobazam tablets or oral suspension and be unable to take it because a difference in inactive ingredients would, in the prescriber's judgment, cause a significant allergy or serious adverse reaction.

    Authorization, Coding, and Denial Risks

    Prior Authorization

    Prior Authorization and Specialist Involvement

    Prior authorization is required for benefit coverage of clobazam. Initial approval requires the medication to be prescribed by, or prescribed in consultation with, a physician who specializes in the condition being treated because of the specialized evaluation, diagnosis, and monitoring required.

    • Obtain prior authorization before requesting benefit coverage.
    • Document the prescribing specialist or specialist consultation for initial approval.
    • Approvals are provided for the duration specified by the policy.
    Step Therapy

    Brand Onfi Exception — Employer Plans

    For Employer Plans, coverage of brand Onfi requires a prior trial of the bioequivalent generic product and documentation that the patient cannot take the generic because of an inactive-ingredient formulation difference that would cause, according to the prescriber, a significant allergy or serious adverse reaction.

    Clinical Background

    Lennox-Gastaut syndrome is a severe epileptic and developmental encephalopathy that commonly begins between ages 3 and 5. It is associated with multiple seizure types, particularly atonic and tonic seizures, substantial morbidity, and frequent treatment resistance.

    Condition Definitions

    Lennox-Gastaut syndrome (LGS)
    DefinitionA severe epileptic and developmental encephalopathy associated with substantial morbidity and mortality.
    Typical onsetMost often begins between 3 and 5 years of age.
    Characteristic seizuresSeveral seizure types may occur, most commonly atonic seizures involving sudden loss of muscle tone and limpness, and tonic seizures.
    Treatment responseSeizures associated with LGS are usually resistant to treatment.
    Dravet syndrome
    DefinitionA rare genetic epileptic encephalopathy involving dysfunction of the brain and marked by frequent and/or prolonged seizures.
    Policy Summary
    PayerCigna
    PolicyAntiseizure Medications - Clobazam Products
    Policy CodePolicy IP0106
    Change TypeAdministrative updateno material clinical or coverage changes
    Effective DateNovember 15, 2026
    Last ReviewOct 29, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and have initial clobazam therapy prescribed by or provided in consultation with a physician who specializes in the condition being treated.
    SourceLink
    On This Page
    Covered and Noncovered UsesInitial Therapy RequirementsContinuation of TherapyBrand Onfi Step RequirementAuthorization, Coding, and Denial RisksClinical BackgroundCondition Definitions
    The patient is currently receiving clobazam and is responding to therapy as determined by the prescriber.

    Examples of response include reduced seizure severity, frequency, and/or duration from baseline before clobazam was initiated.

  1. Preferred product criteria are met for the requested product.
  2. Continuation therapy

    • The patient is currently receiving clobazam and is responding to therapy as determined by the prescriber.

      Examples of response include reduced seizure severity, frequency, and/or duration from baseline before clobazam was initiated.

  3. Preferred product criteria are met for the requested product.
  4. Dravet syndrome initial therapy

    Approve for 1 year when all initial-therapy requirements are met.

    • The patient is at least 2 years of age.Age ≥ 2 years
    • The medication is prescribed by or in consultation with a neurologist.
    • Preferred product criteria are met for the requested product.

    Treatment-refractory seizures or epilepsy initial therapy

    Approve for 1 year when all initial-therapy requirements are met.

    • The patient is at least 2 years of age.Age ≥ 2 years
    • The patient has tried and/or is concomitantly receiving at least two other antiseizure medications.At least two other antiseizure medications

      Examples include valproic acid, lamotrigine, topiramate, clonazepam, levetiracetam, zonisamide, rufinamide, and felbamate.

    • The medication is prescribed by or in consultation with a neurologist.
    • Preferred product criteria are met for the requested product.
    • Applies to Onfi clobazam tablets and oral suspension.
    • Document the attempted generic clobazam tablets or oral suspension trial.
    • Identify the relevant inactive-ingredient difference, such as dyes, fillers, or preservatives, and the resulting significant allergy or serious adverse reaction.
    Step Therapy

    Brand Onfi Exception — Individual and Family Plans

    For Individual and Family Plans, coverage of brand Onfi requires a prior trial of the bioequivalent generic product and documentation that the patient cannot take the generic because of an inactive-ingredient formulation difference that would cause, according to the prescriber, a significant allergy or serious adverse reaction.

    • Applies to Onfi clobazam tablets and oral suspension.
    • Document the attempted generic clobazam tablets or oral suspension trial.
    • Identify the relevant inactive-ingredient difference, such as dyes, fillers, or preservatives, and the resulting significant allergy or serious adverse reaction.
    Denial Risk

    Noncovered Use May Be Denied

    Clobazam for any use outside the policy’s covered uses is not covered and may be denied. Confirm that the requested indication falls within a covered use before submitting the request.

    • Noncovered indications present a denial risk.
    • Do not submit clobazam for an indication outside the three covered uses as a covered request.
    Denial Risk

    Other Uses Are Not Medically Necessary

    The policy considers clobazam for any other use not medically necessary. Requests for such uses may be denied unless the policy is updated to address new published data.

    • Document the covered indication supporting treatment.
    • Expect a medical-necessity denial for uses outside the covered indications.
    Billing Rule

    Use Applicable Covered Codes

    Submit the most appropriate covered diagnosis and/or procedure codes effective on the submission date. Claims or requests without applicable covered code(s) may be denied as not covered.

    • Verify that the diagnosis or procedure codes support the requested clobazam use under the policy.
    • Services billed for conditions or diagnoses not covered by the policy are not reimbursable.
    • The applicable benefit plan document and relevant laws or regulations may supersede the policy.
    Typical onset
    Seizures generally begin during the first year of life in an otherwise healthy infant.
    Seizure featuresAffected individuals can develop many seizure types, including myoclonic, tonic-clonic, absence, atypical absence, atonic, focal aware or impaired awareness, and status epilepticus.
    Treatment responseMost seizures are refractory to medications, and two or more antiseizure medications are often needed for control.